ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0731

Remote Monitoring of Chronic Inflammatory Musculoskeletal Diseases– Results of the Digireuma Feasibility Study
Abstract Number: 1069

Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study
Abstract Number: 0514

Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
Abstract Number: 1543

Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
Abstract Number: 1314

Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Abstract Number: 1026

Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
Abstract Number: 0851

Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis
Abstract Number: 2069

Responsiveness of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Abstract Number: 0589

Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation
Abstract Number: 0103

Retention in Rheumatology Care and Receipt of Lupus-Specific Serologic Testing Among Young Adults with Systemic Lupus Erythematosus: A Medicare Cohort Study
Abstract Number: 0920

Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Abstract Number: 0133

Retention Rate of Targeted Therapies in Erdheim-Chester Disease
Abstract Number: 1434

Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
Abstract Number: 0927

Review of 167,990 Same Day RAPID3, CDAI Scores for 61,312 Patients Receiving DMARD Treatment for Rheumatoid Arthritis; Evaluations of Disease Assessments and Treatment Discontinuation
Abstract Number: 0061

Rheumatic Diagnostic Code Trajectories for Patients with RA and SLE in a U.S. Rheumatology Registry

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].